Dear @nzq21p -

Please reference the following article from cancer.gov titled "More Immunotherapy Options Approved for Treating Endometrial Cancer":
https://www.cancer.gov/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy
Each patient's oncologist will determine the best treatment plan for her based upon the type of tumor, it seems, and less about the grade.

If the endometrial cancer is low-grade but high-stage, it means that:

- Low-grade refers to the cancer cells' appearance under a microscope. They resemble normal cells and are less aggressive, indicating a slower growth rate.
- High-stage refers to the cancer's extent and spread. Despite being low-grade, the cancer has spread to other parts of the body, such as lymph nodes, organs, or distant sites.

In this scenario:

- Treatment may be more extensive due to the cancer's advanced stage, potentially including surgery, radiation, chemotherapy, or a combination.
- Prognosis (outlook) may be less favorable due to the cancer's spread, despite its slower growth rate.
- Regular monitoring and follow-up care are crucial to manage the cancer and address any potential recurrence.

The cancer. government article helped to address my concerns about being on the drug for two years:

"When endometrial cancer is found early, it can often be cured with surgery alone or surgery followed by radiation or chemotherapy. However, the prognosis is poor for people with endometrial cancer that has spread (metastasized) or returned after initial treatment.

FDA had already approved pembrolizumab and dostarlimab to be used alone to treat people with advanced dMMR endometrial cancer that worsened after initial chemotherapy. The approvals were based on clinical trials in which both drugs improved progression-free survival.

Those positive results led researchers to test these drugs as part of the initial treatment of people with advanced endometrial cancer."

I trust this information helps to clarify ESS treatment options for all.

Blessings,
CC